医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

2024年06月10日 AM09:00
このエントリーをはてなブックマークに追加


 

BEIJING

Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that against the backdrop of increasing global challenges, the Company is mobilizing its resources to actively fulfill its corporate social responsibility and is closely monitoring international humanitarian needs and collaborating with relevant organizations and groups to provide essential support for international medical aid.

Amidst evolving global dynamics, numerous regions face pressing humanitarian needs. The Company, renowned for its expertise in digital marketing and commitment to social responsibility, is leveraging its capabilities to assist those in need.

HAO has established a dedicated service team, collaborating closely with international medical aid organizations to assess frontline medical supply requirements. Simultaneously, the Company is sourcing various urgently needed humanitarian relief supplies including medical equipment, pharmaceuticals, and protective gear, while meticulously planning donation strategies and delivery logistics.

Mr. Zhen Fan, Chairman and Chief Executive Officer of the Company, commented, “We firmly believe that corporate success is rooted in societal support and trust. Therefore, amid global challenges, the Company has a unique opportunity to make meaningful contributions to society. Through our international humanitarian aid initiative, the Company aims to play a significant role in alleviating humanitarian crises worldwide.

“Furthermore, the Company invites other companies and individuals to join this collaborative effort, because a collective action is needed to address global humanitarian challenges effectively.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240609519886/en/

CONTACT

For more information, please contact:

Investor Relations

WFS Investor Relations Inc.

Janice Wang, Managing Partner

Email: services@wealthfsllc.com

Phone: +86 13811768599

+1 628 283 9214

同じカテゴリーの記事 

  • PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
  • Technology Holdings就领先的医疗技术产品设计和工程咨询公司Design + Industry战略性售予Capgemini的事宜向其提供咨询服务
  • Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
  • Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris
  • Southeast Asian Countries Lead in Positive Experiences